BioPharmSignal logoBioPharmSignal

Biotech News

MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026

MoonLake Immunotherapeutics (MLTX)MoonLake ImmunotherapeuticsClinical readout

Results from the Phase 3 VELA clinical trials at Week 52 in adults with moderate-to-severe hidradenitis suppurativa (HS) demonstrate sonelokimab’s (SLK) potential best-in-class and best-in-disease profile, with consistent responses that are higher than those observed in trials of competing agents

Related news

MLTXMoonLake Immunotherapeutics2026-08-10 11:00 EST

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

STTKShattuck Labs2026-10-01 11:00 EST

Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development

REGNRegeneron Pharmaceuticals2026-10-01 15:30 EST

Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss

CLDXCelldex Therapeutics2026-09-22 10:58 EST

Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints

KYTXKyverna Therapeutics2026-09-24 10:00 EST

Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis

GPCRStructure Therapeutics2026-09-08 12:00 EST

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

BMYBMYBristol-Myers Squibb Company2026-09-08 10:59 EST

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...

NRIXNurix Therapeutics2026-08-04 11:00 EST

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

CLDXCelldex Therapeutics2026-07-21 20:01 EST

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis

ATYRaTyr Pharma2026-07-15 12:00 EST

aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026

View all latest news

MoonLake Immunotherapeutics

Nanobody-Based Immunology MoonLake Immunotherapeutics develops therapies for inflammatory diseases using Nanobodies, compact antibody-derived proteins designed for tissue penetration, molecular stability and multivalent target binding. Sonelokimab Sonelokimab is a trivalent Nanobody that binds IL-17A and IL-17F while also interacting...

Recent company news

MLTXMoonLake Immunotherapeutics2026-08-10 11:00 EST

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

MLTXMoonLake Immunotherapeutics2026-06-24 03:08 EST

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering

MLTXMoonLake Immunotherapeutics2026-06-22 20:01 EST

MoonLake Immunotherapeutics Announces Proposed Public Offering

MLTXMoonLake Immunotherapeutics2026-06-21 21:00 EST

MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026

MLTXMoonLake Immunotherapeutics2026-05-10 13:00 EST

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

Stock data

Close
11.47 USD
Market cap
1.32B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States